French-founded biotech Smart Immune has made significant headway in stimulating the thymus, a small gland with a huge immunological impact which rarely finds itself as a key clinical target. The company is now investigating the impact that two of its ProTcell products in patients with severe combined immunodeficiency and leukemia could have.
“The thymus is absolutely instrumental in arming your T-cells to fight viruses and cancers,” said Smart Immune CEO Karine Rossignol. “If they don’t go into the thymus to be educated, they’re not efficient to protect you from cancers and infections. We have created this company to fight against both.”
An often-overlooked aspect of the lymphatic system, the thymus gland sits in the chest between the lungs and makes T-cells....
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
